Replies to post #11041 on Tao Synergies Inc (TAOX)

[Cyosol]

Looks like they changed the primary outcome measure from a week 13 + 15 average baseline change to just a week 13 baseline change.

Got any ideas for why they might have done this? The last trial showed the most dramatic improvement in patients between week 13 and 15 after all.

[grich1]

Doc,

Is your time estimate below still the same?

“
Patients are observed for 30 more days as part of the protocol, so the study should be complete 6/27/19 +/- 1-3 days. Study completion should get a PR the next day so we should know for certain by 6/28/19 or 7/1/2019 at the latest. Topline release should be 6-10 weeks later, 8/8/19 to 9/5/19.”

Did the July 15 PR change anything?


NEW YORK, July 15, 2019 /PRNewswire/ -- NeurotropeInc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that the Company has concluded data collection in its confirmatory Phase 2 double blind, placebo controlled clinical trial of Bryostatin-1 in the treatment of moderately severe to severe AD.


Thanks